MNMD241220P4000
- 0.10
- 0.000.00%
Mind Medicine Newsroom
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $21
RBC Capital Remains a Buy on Mind Medicine (MNMD)
Mind Medicine Analyst Ratings
Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55
Mind Medicine's Strategic Advancements and Clinical Progress Drive Buy Rating
CCORF Maintains Mind Medicine(MNMD.US) With Buy Rating, Raises Target Price to $16
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Cuts Target Price to $21
RBC Capital Keeps Their Buy Rating on Mind Medicine (MNMD)
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)
Leerink Partners Initiates Mind Medicine(MNMD.US) With Buy Rating, Announces Target Price $20
Mind Medicine Price Target Raised to $55.00/Share From $35.00 by HC Wainwright & Co.
Mind Medicine Is Maintained at Buy by HC Wainwright & Co.
Mind Medicine Analyst Ratings
Strong Buy Rating on Mind Medicine Backed by Positive Developments in MM120 Trials and Solid Financial Standing
Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18
Strong Financial Position and Promising Clinical Trials Underpin Buy Rating for Mind Medicine
Leerink Partners Maintains Mind Medicine(MNMD.US) With Buy Rating
Buy Rating Affirmed for Mind Medicine With Promising Phase 3 Trials on the Horizon